Please wait while we load the requested 10-Q report or click the link below:
Script used in the previously announced Theravance Biopharma, Inc. conference call held May 9, 2017
1Q 2017 Financial Results Conference Call
May 9, 2017 2:00 p.m. PT/5:00 p.m. ET
Alex Dobbin, Head of Investor Relations
Good afternoon, everyone, and thank you for joining our first quarter 2017 financial results conference call and webcast. With me on the call today are Rick Winningham, Chief Executive Officer; Renee Gala, Chief Financial Officer; and Brett Haumann, Chief Medical Officer. Following our prepared remarks, we will open the call for questions. A copy of the press release and the slides accompanying this call can be downloaded from our website, or you can call investor relations at 650-808-4045 and well be happy to assist you.
Before we get started, we would like to remind you that this conference call will contain forward-looking statements which involve certain risks and uncertainties including statements about our product pipeline, expected benefits of our products, the anticipated timing of trial results and regulatory filings, and expected financial results.
Information concerning factors that could cause results to differ materially from our forward-looking statements are described further in the Companys filings made with the Securities and Exchange Commission.
The following information was filed by Theravance Biopharma, Inc. (TBPH) on Wednesday, May 10, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Theravance Biopharma, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Theravance Biopharma, Inc..